Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Actinic Keratosis Treatment Companies

ID: MRFR/Pharma/1746-CR
95 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Actinic Keratosis Treatment companies are dedicated to addressing this common skin condition. Through research, development, and distribution, they provide advanced treatments, contributing to the effective management of actinic keratosis and reducing the risk of skin cancer development.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Actinic Keratosis Treatment Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)7.61%
2024 Market Size$ 9.75 Billion
2025 Market Size$ 10.59 Billion
2035 Market Size$ 21.93 Billion

Key Players

AstraZeneca
Bristol-Myers Squibb
Novartis
Amgen
Galderma
Medytox
Opportunities
  • Market Growth Projections
  • Growing Geriatric Population
  • Regulatory Support and Approval

Top Industry Leaders in the Actinic Keratosis Treatment Market

Actinic Keratosis Treatment Key Companies
ย 
Latestย Actinic Keratosis Treatmentย Companies Update:

Biofrontera AG commercially launches AMELUZ in Finland: This product approval expands Biofrontera's reach in Europe and offers an alternative to traditional photodynamic therapy with its BF-RhodoLED lamp

Almirall receives FDA approval for Klisyri (tirbanibulin): This new topical cream offers a once-daily application option for AK treatment, potentially improving patient compliance.

Cipher Pharmaceuticals Inc. expands distribution of Zyclaraยฎ (imiquimod): This established topical cream sees continued market penetration, solidifying its position in the AK treatment landscape.

Sun Pharmaceutical Industries Ltd. acquires Taro Pharmaceuticals Holdings Inc.: This acquisition consolidates Sun Pharma's position in the dermatology market, potentially impacting AK treatment offerings.

Valeant Pharmaceuticals announces positive Phase 3 results for Duavlir (alimetinib/ingenol mebutate): This investigational topical gel demonstrates promising efficacy and safety in AK treatment, potentially entering the market soon.

List ofย Actinic Keratosis Treatmentย Key companies in the market
  • Stanford Chemicals (US)
  • Alma Lasers (Israel),ย 
  • 3M (US),
  • Sun Pharmaceutical Industries Ltd. (India),
  • Galderma S.A (Switzerland),
  • Leo Pharma (Denmark),
  • Valeant Pharmaceuticalsย (US),
  • BioLineRx (Israel),
  • Cipher Pharmaceuticals Inc (Canada),
  • Biofrontera AG (Germany)